Optimizing the Timing of PCSK9 Therapy After an ASCVD Event

The panelists explore the question of when to initiate PCSK9 therapy following an ASCVD event. They note that evidence from large trials and real-world data supports the early introduction of PCSK9 inhibitors, often before hospital discharge, to maximize LDL-C lowering and reduce the risk of recurrent events. The experts point out that patients remain at the highest risk for a second event in the first year after an acute coronary syndrome, making this window crucial for aggressive lipid management. They also discuss how logistical barriers—such as prior authorizations and coordination between inpatient and outpatient teams—often delay therapy initiation. Early administration, the panelists emphasize, can improve adherence and long-term outcomes, particularly when combined with educational efforts and structured follow-up. Overall, the experts agree that integrating PCSK9 inhibitors into the acute-to-chronic care continuum represents a practical and evidence-based approach to optimizing secondary prevention in high-risk ASCVD patients.